Nanatinostat - Viracta Therapeutics

Alternative Names: CHR-3996; Tractinostat; VRx-3996

Latest Information Update: 06 Dec 2018

Price : $50 ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Chroma Therapeutics
Developer Chroma Therapeutics; Viracta Therapeutics
Class Amides; Antineoplastics; Pyrimidines; Quinolines; Small molecules
Mechanism of Action Histone deacetylase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Lymphoma
Phase I/II Multiple myeloma
Preclinical Gastric cancer; Nasopharyngeal cancer; Post-transplant lymphoproliferative disorder
No development reported Solid tumours

Most Recent Events

04 Dec 2018 Viracta plans a clinical trial for the treatment of EBV-associated Solid tumors in 2019
03 Dec 2018 Viracta Therapeutics and Shenzhen Salubris Pharmaceuticals enters into an exclusive collaboration and licence agreement for Cancer (Viral associated) in China
12 Apr 2018 VRx 3996 is now called Tractinostat

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight